Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (394)	11/22/1999 9:51:00 PM
From: WTDEC	Respond to of 666

PB, Thanks for a great post! Nice sites too! Best regards, Walter

To: Pseudo Biologist who wrote (394)	11/22/1999 10:02:00 PM
From: Bob L	Respond to of 666

Thanks PB. Very instructive.

To: Pseudo Biologist who wrote (394)	11/22/1999 11:12:00 PM
From: Bob L	Read Replies (2) \| Respond to of 666

TITLE: Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma [In Process Citation] AUTHORS: Chinn PC; Leonard JE; Rosenberg J; Hanna N; Anderson DR AUTHOR AFFILIATION: IDEC Pharmaceuticals Inc., San Diego, CA 92121, USA. SOURCE: Int J Oncol 1999 Nov;15(5):1017-25 [MEDLINE record in process] CITATION IDS: PMID: 10536187 UI: 20007943 ABSTRACT: A high-affinity IgG1 kappa murine monoclonal anti-CD20 antibody (IDEC- 2B8) was developed for radioimmunotherapy of non-Hodgkin's B-cell lymphoma. A stable immunoconjugate (Zevalintrade mark) was prepared by reacting IDEC-2B8 with a derivative of diethylenetriaminepentaacetic acid, designated MX-DTPA, a chelator exhibiting high affinity and retention for 90Y. Zevalin exhibited antigen specificity, human tissue reactivity, and preclinical safety profile comparable to the native antibody. The conjugate radiolabeled with 90Y (90Y-Zevalin) or 111In (111In-Zevalin) exhibited excellent retention of immunoreactivity with radioincorporations >95%. The radiolabeled conjugates formulated in PBS containing human serum albumin were stable in vitro at 4 degrees C for 48 h as indicated by negligible loss of radioisotope and retention of binding to CD20+ cells. In vitro human serum stability studies at 37 degrees C with 90Y-Zevalin indicated that loss of 90Y from the conjugate was minimal, averaging 1% per day. Biodistribution studies in BALB/c mice confirmed the in vitro stability of 90Y-Zevalin and 111In- Zevalin. In particular, excellent in vivo retention of 90Y by the conjugate was demonstrated by minimal bone accumulation.

To: Pseudo Biologist who wrote (394)	11/28/1999 11:45:00 PM
From: RWReeves	Read Replies (1) \| Respond to of 666

PB- from a press release by Neorx in August Have not seen much on them-could they be another serious player? "Our Pretarget® -Lymphoma study with a conjugate using a commercially available antibody also produced several complete responses, including a patient who had failed a previous marrow transplant," said Dr. Abrams. "Our scientists have now made in bacteria a cost-effective, simplified replacement of that conjugate that looks even better in pre-clinical testing than the molecule that produced the clinical results." Pretarget technology employs separate injections of targeting antibody and therapeutic agent such as radiation that join where the antibody pre-localized. Conventional antibody targeting, by contrast, links the antibody and the therapeutic agent together prior to injection, thereby imparting the long circulation time of the antibody to the therapeutic. Pretarget has enabled NeoRx's patients to receive 4-5 times the dose of radiation than the conventional approach. In its lymphoma study, less than 10 patients received about three-fold the dose of the conventional agents without reaching a maximum tolerated dose (MTD). I think they are using a Holmium 166 Beta emitter which might be better than a gamma source and the dosimetry involved. I'm looking into NERX and their odd preferred-NERXP for the BTFLTAB thread. RWR